Non-human Primate (NHP) Model: A Valuable Tool For Investigation Of The Pathogenesis Of Tuberculosis (TB) And Preclinical Evaluation Of New Vaccine Strategies | 38683
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand
Google scholar citation report
Citations : 1536

Journal of Biotechnology & Biomaterials received 1536 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Non-human primate (NHP) model: a valuable tool for investigation of the pathogenesis of Tuberculosis (TB) and preclinical evaluation of new vaccine strategies

World Bio Summit & Expo

Ivanela Kondova

Biomedical Primate Research Centre, The Netherlands

Posters-Accepted Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.047

Tuberculosis (TB) remains a significant cause of morbidity and mortality worldwide with nearly 9 million new infections annually and 1.4 million deaths. The infection is relatively difficult to treat with antibiotics and the spread of drug resistant organisms define the need for using more appropriate animal models closely related to humans. The only vaccine available, Bacillus Chalmette Guerin (BCG), shows variable efficacy ranging from 0-80% in different geographic populations. One of the important lines of research at Biomedical Primate Research Centre (BPRC) in Netherlands is the investigation of the pathogenesis and protective immunity of disease and preclinical evaluation of new vaccine strategies. We use non-human primates (NHP) and macaques specifically, which in contrast to all other TB models are closely related to humans and naturally susceptible to Mycobacterium tuberculosis (M.tb) and present the best recapitulation of the human disease. In the years ahead, TB research will try and further build on its expertise in preclinical vaccine studies. Future efforts shall focus also on improvement/refinement of the modeling towards relevant readout of protective TB vaccine effects, which may include advanced bio-imaging. The rationale for improved modeling will be sought in fundamental research strategies that can contribute to a better understanding of the (early) host response against M.tuberculosis and TB pathogenesis. Further integration of applied and basic research efforts will leverage towards improvement of TB therapy as well as sustainability of TB vaccine research and TB drug research and development at BPRC.

Ivanela Kondova is the head of Division of Pathology and Microbiology at Biomedical Primate Research Center in Netherlands. She is involved in research projects for global pharmaceutical industry, World Health Organization and many different academic Institutions. She was trained as a Veterinary pathologist at the New England Primate Research Center - Harvard Medical School in Massachusetts, United States. She gained extensive experience in the area of infectious diseases while she was working at Tufts Veterinary University, MA, US. She has published more than 50 scientific papers in peer-reviewed journals.

Email: [email protected]